Pre-erythrocytic stage malaria vaccines: time for a change in path

Current Opinion in Microbiology

Volumn 10, Issue 4, 2007, Pages 371-378

  Druilhe, Pierre ^a   Barnwell, John W ^b  

^a INSTITUT PASTEUR   (France)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; MALARIA VACCINE; PRE ERYTHROCYTIC STAGE VACCINE; SPOROZOITE VACCINE; UNCLASSIFIED DRUG;

DEFENSE MECHANISM; MALARIA; MEDICAL RESEARCH; NONHUMAN; REVIEW; SPOROZOITE;

ANIMALS; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM; SPOROZOITES;

MUS;

EID: 34548671923     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2007.07.009     Document Type: Review

References (69)

1. Garnham P.C. Malaria Parasites and Other Haemosporidia (1966), Blackwell Publishing
2. Jeffery G.M. Epidemiological significance of repeated infections with homologous and heterologous strains and species of Plasmodium. Bull World Health Organ 35 (1966) 873-882
3. Druilhe P.L., Renia L., and Fidock D.A. In: Sherman I.W. (Ed). Immunity to Liver Stages (1998), ASM Press, Washington, DC 513-543. This is a detailed review of the major differences between blood and liver schizogony, of the accumulated evidence that favors the role of liver stage antigens in attenuated sporozoite-induced immunity, and the wide diversity of defense mechanisms that occur depending on the host and parasite combination being studied.
4. Carter R., Mendis K.N., Miller L.H., Molineaux L., and Saul A. Malaria transmission-blocking vaccines-how can their development be supported?. Nat Med 6 (2000) 241-244
5. Richie T. High road, low road? Choices and challenges on the pathway to a malaria vaccine. Parasitology 133 Suppl (2006) S113-S144
6. Epstein J.E., Giersing B., Mullen G., Moorthy V., and Richie T.L. Malaria vaccines: are we getting closer?. Curr Opin Mol Ther 9 (2007) 12-24. This reference is a comprehensive detailed review of recent malaria vaccine trials performed over the past few years.
7. Russell P.F., Mulligan H.W., and Mohan B.N. Inactivation of Plasmodium gallinaceum sporozoites infectivity. J Malaria Inst India 4 (1941) 15-24
8. Mulligan H.W., Russel P.F., and Mohan B.N. Active immunization of fowls against Plasmodium gallinaceum by injections of killed homologous sporozoites. J Malaria Inst India 4 (1941) 25-34
9. Nussenzweig R., Vanderberg J., and Most H. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. IV. Dose response, specificity and humoral immunity. Mil Med 134 (1969) 1176-1182
10. Nussenzweig R.S., Vanderberg J., Most H., and Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216 (1967) 160-162
11. Clyde D.F., McCarthy V.C., Miller R.M., and Hornick R.B. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 266 (1973) 398-403
12. Clyde D.F. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 24 (1975) 397-401
13. Rieckmann K.H., Carson P.E., Beaudoin R.L., Cassells J.S., and Sell K.W. Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 68 (1974) 258-259
14. Rieckmann K.H., Beaudoin R.L., Cassells J.S., and Sell K.W. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ 57 Suppl 1 (1979) 261-265
15. Clyde D.F., Most H., McCarthy V.C., and Vanderberg J.P. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 266 (1973) 169-177. This paper is a milestone in malaria vaccine history, where the work by Drs J Vanderberg and RS Nussenzweig in mice was for the first time scaled up and effectively demonstrated in human volunteers.
16. Ozaki L.S., Svec P., Nussenzweig R.S., Nussenzweig V., and Godson G.N. Structure of the Plasmodium knowlesi gene coding for the circumsporozoite protein. Cell 34 (1983) 815-822
17. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., Wellde B.T., Garcon N., Krzych U., and Marchand M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336 (1997) 86-91. This reference, which compares three different adjuvants, constitutes the foundation for the particulate formulation of CS antigen, called RTSS, with the adjuvant ASO2 selected on the basis of induction of cytotoxic T lymphocytes.
18. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K., Glenn G., Ockenhouse C.F., Garcon N., Schwenk R., et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 178 (1998) 1139-1144
19. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., Krzych U., Delchambre M., Voss G., Dowler M.G., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183 (2001) 640-647
20. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., Ballou W.R., Conway D.J., Reece W.H., Gothard P., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001) 1927-1934
21. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., Mandomando I., Spiessens B., Guinovart C., Espasa M., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 (2004) 1411-1420
22. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Aide P., Sigauque B., Milman J., Mandomando I., Bassat Q., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 (2005) 2012-2018
23. Bojang K.A. RTS,S/AS02A for malaria. Expert Rev Vaccines 5 (2006) 611-615
24. Snounou G., Gruner A.C., Muller-Graf C.D., Mazier D., and Renia L. The Plasmodium sporozoite survives RTS,S vaccination. Trends Parasitol 21 (2005) 456-461. This review analyses in critical detail the reasons why there is today little proof for the efficacy of the RTSS vaccine in homologous and heterologous P. falciparum challenges in volunteers and in field studies.
25. Graves P., and Gelband H. Vaccines for preventing malaria (SPf66). Cochrane Database Syst Rev (2006) CD005966
26. Acosta C.J., Galindo C.M., Schellenberg D., Aponte J.J., Kahigwa E., Urassa H., Schellenberg J.R., Masanja H., Hayes R., Kitua A.Y., et al. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania. Trop Med Int Health 4 (1999) 368-376
27. Barder O., Kremer M., and Williams H. Advance market commitments: a policy to stimulate investment in vaccines for neglected diseases. Economist's Voice 3 (2006) 1
28. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., Vuola J.M., Blanchard T.J., Gothard P., Watkins K., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9 (2003) 729-735
29. Moorthy V.S., Imoukhuede E.B., Milligan P., Bojang K., Keating S., Kaye P., Pinder M., Gilbert S.C., Walraven G., Greenwood B.M., et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 1 (2004) e33
30. Walther M., Thompson F.M., Dunachie S., Keating S., Todryk S., Berthoud T., Andrews L., Andersen R.F., Moore A., Gilbert S.C., et al. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun 74 (2006) 2706-2716
31. Dunachie S.J., Walther M., Epstein J.E., Keating S., Berthoud T., Andrews L., Andersen R.F., Bejon P., Goonetilleke N., Poulton I., et al. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 74 (2006) 5933-5942
32. Bejon P., Mwacharo J., Kai O., Mwangi T., Milligan P., Todryk S., Keating S., Lang T., Lowe B., Gikonyo C., et al. A Phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials 1 (2006) e29
33. Li S., Locke E., Bruder J., Clarke D., Doolan D.L., Havenga M.J., Hill A.V., Liljestrom P., Monath T.P., Naim H.Y., et al. Viral vectors for malaria vaccine development. Vaccine 25 (2007) 2567-2574
34. Rodrigues E.G., Zavala F., Nussenzweig R.S., Wilson J.M., and Tsuji M. Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 16 (1998) 1812-1817
35. Ophorst O.J., Radosevic K., Havenga M.J., Pau M.G., Holterman L., Berkhout B., Goudsmit J., and Tsuji M. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 74 (2006) 313-320
36. Mueller A.K., Labaied M., Kappe S.H., and Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433 (2005) 164-167. This paper provides the foundation for genetically attenuated vaccines by showing that knocking out a gene expressed in pre-erythrocytic stage can generate a crippled parasite unable to complete intra-hepatic development, yet able to induce protection.
37. Mueller A.K., Camargo N., Kaiser K., Andorfer C., Frevert U., Matuschewski K., and Kappe S.H. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci USA 102 (2005) 3022-3027
38. van Dijk M.R., Douradinha B., Franke-Fayard B., Heussler V., van Dooren M.W., van Schaijk B., van Gemert G.J., Sauerwein R.W., Mota M.M., Waters A.P., et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci USA 102 (2005) 12194-12199
39. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., Sacci J., de la Vega P., Dowler M., Paul C., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185 (2002) 1155-1164
40. Mellouk S., Lunel F., Sedegah M., Beaudoin R.L., and Druilhe P. Protection against malaria induced by irradiated sporozoites. Lancet 335 (1990) 721
41. Scheller L.F., and Azad A.F. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc Natl Acad Sci USA 92 (1995) 4066-4068
42. Ballou W.R. Obstacles to the development of a safe and effective attenuated pre-erythrocytic stage malaria vaccine. Microbes Infect (2007)
43. Druilhe P., Sabchareon A., Bouharountayoun H., Oeuvray C., and Perignon J.L. In vivo veritas-lessons from immunoglobulin-transfer experiments in malaria patients. Ann Trop Med Parasitol (1997)
44. Druilhe P., Hagan P., and Rook G.A. The importance of models of infection in the study of disease resistance. Trends Microbiol 10 (2002) S38-S546
45. Chatterjee S., Perignon J.L., Van Marck E., and Druilhe P. How reliable are models for malaria vaccine development? Lessons from irradiated sporozoite immunizations. J Postgrad Med 52 (2006) 321-324
46. Chatterjee S., Druilhe P., and Wery M. Irradiated sporozoites prime mice to produce high antibody titres upon viable Plasmodium berghei sporozoite challenge, which act upon liver-stage development. Parasitology 118 Pt 3 (1999) 219-225
47. Chatterjee S., Ngonseu E., Van Overmeir C., Correwyn A., Druilhe P., and Wery M. Rodent malaria in the natural host-irradiated sporozoites of Plasmodium berghei induce liver-stage specific immune responses in the natural host Grammomys surdaster and protect immunized Grammomys against P. berghei sporozoite challenge. Afr J Med Med Sci 30 Suppl (2001) 25-33
48. Nardin E.H., Nussenzweig V., Nussenzweig R.S., Collins W.E., Harinasuta K.T., Tapchaisri P., and Chomcharn Y. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med 156 (1982) 20-30
49. Kumar K.A., Sano G., Boscardin S., Nussenzweig R.S., Nussenzweig M.C., Zavala F., and Nussenzweig V. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444 (2006) 937-940
50. Webster H.K., Boudreau E.F., Pang L.W., Permpanich B., Sookto P., and Wirtz R.A. Development of immunity in natural Plasmodium falciparum malaria: antibodies to the falciparum sporozoite vaccine 1 antigen (R32tet32). J Clin Microbiol 25 (1987) 1002-1008
51. Fidock D.A., Bottius E., Brahimi K., Moelans I.I., Aikawa M., Konings R.N., Certa U., Olafsson P., Kaidoh T., Asavanich A., et al. Cloning and characterization of a novel Plasmodium falciparum sporozoite surface antigen, STARP. Mol Biochem Parasitol 64 (1994) 219-232
52. Ockenhouse C.F., Sun P.F., Lanar D.E., Wellde B.T., Hall B.T., Kester K., Stoute J.A., Magill A., Krzych U., Farley L., et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 177 (1998) 1664-1673
53. Rodrigues M.M., Cordey A.S., Arreaza G., Corradin G., Romero P., Maryanski J.L., Nussenzweig R.S., and Zavala F. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol 3 (1991) 579-585
54. Good M.F., and Miller L.H. Involvement of T cells in malaria immunity: implications for vaccine development. Vaccine 7 (1989) 3-9
55. Hoffman S.L., Weiss W., Mellouk S., and Sedegah M. Irradiated sporozoite vaccine induces cytotoxic T lymphocytes that recognize malaria antigens on the surface of infected hepatocytes. Immunol Lett 25 (1990) 33-38
56. Webster D.P., Dunachie S., Vuola J.M., Berthoud T., Keating S., Laidlaw S.M., McConkey S.J., Poulton I., Andrews L., Andersen R.F., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 102 (2005) 4836-4841
57. Garcon N., Heppner D.G., and Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2 (2003) 231-238
58. Lalvani A., Moris P., Voss G., Pathan A.A., Kester K.E., Brookes R., Lee E., Koutsoukos M., Plebanski M., Delchambre M., et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 180 (1999) 1656-1664
59. Druilhe P., and Marchand C. From sporozoite to liver stages: the saga of the irradiated sporozoite vaccine. In: McAdam K. (Ed). New Strategies in Parasitology (1989), Churchill Livingstone 39-48
60. Scheller L.F., Stump K.C., and Azad A.F. Plasmodium berghei: production and quantitation of hepatic stages derived from irradiated sporozoites in rats and mice. J Parasitol 81 (1995) 58-62
61. Heppner D.G., et al. In: Levine M., Kaper J.B., Rappuoli R., Liu M., and Good M.F. (Eds). New Generation Vaccines (2004), Marcel Dekker, New York
62. Daubersies P., Thomas A.W., Millet P., Brahimi K., Langermans J.A., Ollomo B., BenMohamed L., Slierendregt B., Eling W., Van Belkum A., et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 6 (2000) 1258-1263. This paper describes the discovery of the first malaria vaccine antigen identified by means other than rodent immune responses, in this case, by differences in human immune responses from malaria protected versus non-protected volunteers.
63. Marchand C., and Druilhe P. How to select Plasmodium falciparum pre-erythrocytic antigens in an expression library without defined probe. Bull World Health Organ 68 Suppl (1990) 158-164
64. Gruner A.C., Hez-Deroubaix S., Snounou G., Hall N., Bouchier C., Letourneur F., Landau I., and Druilhe P. Insights into the P. yoelii hepatic stage transcriptome reveal complex transcriptional patterns. Mol Biochem Parasitol 142 (2005) 184-192
65. Grüner A.C., Snounou G., Brahimi K., Letourneur F., Renia L., and Druilhe P. Pre-erythrocytic antigens of P. falciparum: from rags to riches?. Trends Parasitol 19 (2003) 47-78
66. Guerin-Marchand C., Druilhe P., Galey B., Londono A., Patarapotikul J., Beaudoin R.L., Dubeaux C., Tartar A., Mercereau-Puijalon O., and Langsley G. A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature 329 (1987) 164-167
67. Perlaza B.L., Zapata C., Valencia A.Z., Hurtado S., Quintero G., Sauzet J.P., Brahimi K., Blanc C., Arevalo-Herrera M., Druilhe P., et al. Immunogenicity and protective efficacy of Plasmodium falciparum liver-stage Ag-3 in Aotus lemurinus griseimembra monkeys. Eur J Immunol 33 (2003) 1321-1327
68. Hillier C.J., Ware L.A., Barbosa A., Angov E., Lyon J.A., Heppner D.G., and Lanar D.E. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect Immun 73 (2005) 2109-2115
69. Snow R.W., Trape J.F., and Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol 17 (2001) 593-597